{"id":"W4283803757","doi":"10.15252/emmm.202115230","title":"Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants","year":2022,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Science Foundation; Canadian Institutes of Health Research; Innovative Medicines Initiative; Austrian Science Fund; European Commission; Österreichischen Akademie der Wissenschaften; National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; U.S. Department of Health and Human Services; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Center for Strategic Scientific Initiatives, National Cancer Institute","keywords":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Recombinant DNA; Potency; Coronavirus disease 2019 (COVID-19); Virology; Antibody; Neutralizing antibody; 2019-20 coronavirus outbreak; Chemistry; Microbiology; Biology; Molecular biology; Immunology; Virus; Medicine; Gene; Biochemistry; In vitro","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001444241,0.0003088289,0.0007361078,0.0004611838,0.0002068515,0.00001362516,0.000527332,0.000130493,0.0002845944],"category_scores_gemma":[0.001073438,0.0002735666,0.0002448433,0.001122967,0.0002307686,0.00003715016,0.0005987781,0.001018175,0.0003342111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003171219,"about_ca_system_score_gemma":0.0006623572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005377415,"about_ca_topic_score_gemma":0.00001464695,"domain_scores_codex":[0.9956513,0.0004590982,0.0006259043,0.0008031803,0.001764624,0.0006958996],"domain_scores_gemma":[0.9983205,0.0001807109,0.0001053763,0.0009638201,0.0001528439,0.0002768001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001622418,0.001133548,0.005781583,0.0001039331,0.000614822,0.02214573,0.001663913,0.00001017629,0.8786223,0.001821378,0.08063691,0.005843318],"study_design_scores_gemma":[0.007984571,0.00520948,0.003946314,0.0001434159,0.0003278054,0.0007735905,0.001017065,0.0003486252,0.03966742,0.0004043238,0.9398226,0.000354843],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9574418,0.0008961926,0.0008118923,0.02131049,0.000881896,0.001107143,0.00001044404,0.0001485118,0.0173916],"genre_scores_gemma":[0.7491667,0.00001148258,0.0003127943,0.2492353,0.0005070394,0.00007529642,0.00001756317,0.00007118612,0.0006026468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8591856,"threshold_uncertainty_score":0.9999716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06518186342974834,"score_gpt":0.4089792007146749,"score_spread":0.3437973372849265,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}